Regado Biosciences, Inc. Announces Closing of Initial Public Offering
BASKING RIDGE, N.J., Aug. 27, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced initial public offering of 10,750,000 shares of common stock, at a public offering price of $4.00 per share, resulting in gross proceeds of $43,000,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Regado Biosciences. All of the common stock was offered by Regado Biosciences. The company's common stock is listed on The NASDAQ Capital Market under the trading symbol "RGDO."
Cowen and Company, LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Canaccord Genuity Inc., Needham & Company, LLC, and Wedbush PacGrow Life Sciences acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 21, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: firstname.lastname@example.org.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. The actively controllable product candidates have the potential to improve outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.
Joshua Drumm, Ph.D./Andrew Mielach
email@example.com; (212) 375-2664
firstname.lastname@example.org; (212) 375-2694
SOURCE Regado Biosciences, Inc.